Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Overview of Sensus Healthcare Inc
Sensus Healthcare Inc is a specialized medical device company that has dedicated over a decade to the development of non-invasive treatment solutions using proprietary superficial radiation therapy (SRT) technology. This innovative treatment method is designed for both oncological and non-oncological skin conditions, including various forms of non-melanoma skin cancers and conditions such as keloids, offering a safe and cost-effective alternative to surgical procedures.
Core Technology and Treatment Solutions
The company utilizes a proprietary low energy x-ray radiation system that underpins its SRT technology. This method enables precise targeting of skin lesions while minimizing damage to surrounding tissues. The approach is rooted in extensive research and development, ensuring that each device deployed not only aligns with current clinical standards but also supports a streamlined treatment process. The primary devices in the company’s portfolio are designed to simplify the treatment procedure while ensuring efficacy and patient safety.
Business Model and Revenue Generation
Sensus Healthcare Inc generates revenue primarily through the sale of its specialized SRT treatment devices alongside an associated service program. The revenue model is based on direct transactions with hospitals, oncology centers, and dermatology practices, particularly in the United States. The company’s sales approach integrates product delivery with ongoing support, positioning Sensus as a comprehensive service provider within the medical device industry. This dual-focus on advanced technology and customer service ensures that clients receive not only the equipment but also the necessary operational expertise to maximize treatment outcomes.
Market Position and Industry Significance
Operating within the competitive realm of medical devices, Sensus Healthcare Inc has carved out a niche by focusing on non-invasive superficial radiation therapy. The technology addresses a clear need in the treatment of skin conditions by reducing the potential risks and complications associated with more invasive procedures. With increasing emphasis on patient safety and cost-effectiveness in healthcare, the company’s offerings are well-positioned to provide value within hospital oncology and dermatology departments. Its emphasis on targeted radiation treatment distinguishes its operational approach from other modalities available in the market.
Operational Focus and Customer Base
The company's operational framework is built around delivering effective treatment solutions through both its high-quality devices and a robust support program. The customer base includes major healthcare providers such as hospital oncology departments and specialized dermatology practices. By prioritizing reliability and clinical efficacy, Sensus Healthcare sustains trust within the medical community, ensuring continuous adoption of its technology in outpatient treatment settings.
Clinical Impact and Safety
At the heart of Sensus Healthcare Inc's offerings is a strong commitment to patient safety and treatment efficacy. The non-invasive SRT technique minimizes the need for surgical intervention, thereby reducing recovery times and potential risks associated with more invasive treatments. This clinical approach not only enhances patient outcomes but also supports operational efficiency in healthcare settings by offering a streamlined alternative that aligns with modern treatment protocols.
Competitive Landscape and Differentiation
Sensus Healthcare Inc operates in a dynamic industry where differentiation is critical. The company sets itself apart through its exclusive focus on superficial radiation therapy, a technology with a clear evidential basis in decades of research and clinical application. Although facing competition from traditional and emerging treatment modalities, Sensus leverages its research-backed technology and dedicated service programs to maintain a distinct foothold in the market. Expertise in both technological innovation and customer service elevates its competitive profile as a trusted provider in the non-invasive medical device segment.
Conclusion
In summary, Sensus Healthcare Inc is a specialized medical device entity that combines technological innovation with secure, non-invasive treatment options. Its use of superficial radiation therapy not only underscores advances in medical device innovation but also reflects the company's commitment to enhancing patient care in the treatment of skin conditions. This comprehensive approach, integrating advanced product development with dedicated service programs, positions Sensus Healthcare as a valued participant in a complex and critical segment of healthcare technology.
Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive and minimally-invasive treatments for skin conditions, has announced its participation in the 37th Annual ROTH Conference. The event is scheduled for March 17-18 in Dana Point, California.
The company, which specializes in treatments for both oncological and non-oncological skin conditions, will be conducting one-on-one meetings with registered investors during the conference. Interested registered attendees can schedule meetings with Sensus Healthcare management through their ROTH representative or by contacting Tirth Patel at Alliance Advisors.
Sensus Healthcare (NASDAQ: SRTS) announces its participation in the 2025 American Academy of Dermatology Annual Meeting, showcasing its commercial and pre-commercial products at Booth #2451. The company will present its full line of Superficial Radiotherapy (SRT) systems, including the SRT-100®, SRT-100+, and SRT-100 Vision™.
The exhibition will feature 'The A.I. Experience,' highlighting new innovations including a prototype handheld ultrasound device for skin lesion identification and the TransDermal Infusion (TDI) product with Sentinel™ IT Solutions. The TDI system, pending regulatory approval, will enable platelet-rich plasma application for hair restoration and has shown potential applications for hyperhidrosis treatment.
The event will take place March 7-11, 2025, at the Orange County Convention Center in Orlando, Florida, featuring over 350 exhibitors and expecting nearly 20,000 attendees.
Sensus Healthcare (NASDAQ: SRTS) has announced the publication of a significant study in the Annals of Plastic Surgery demonstrating the effectiveness of their SRT-100® system in preventing keloid recurrence. The study, conducted at Tri Service Military Hospital in Taiwan, evaluated the combination of surgical keloid excision with primary wound closure followed by Superficial Radiation Therapy (SRT).
The research, involving 12 patients with 16 keloids, showed no keloid recurrence in most patients during follow-up periods exceeding six months. This marks Sensus Healthcare's first study in Asia, with the hospital utilizing the SRT-100® since 2023.
The study's results are particularly significant as keloids, which are benign skin tumors caused by abnormal scar tissue growth, traditionally show high recurrence rates with conventional treatments like corticosteroid injections, cryotherapy, and laser therapy. The integration of SRT targets excess fibroblast activity, addressing the root cause of keloid regrowth.
Sensus Healthcare (NASDAQ: SRTS) has announced the resumption of its share repurchase program, allowing for the purchase of up to $3.0 million of common stock in open-market transactions. The program, initially approved by the Board of Directors in August 2023, has already seen the repurchase of 9,427 shares.
CEO Joe Sardano stated that the company views the current stock price as a compelling opportunity for repurchases, expressing confidence in growth prospects. The company successfully completed a similar $3 million repurchase program in 2022.
The timing and volume of share repurchases will be determined by management based on capital needs, stock price, and market conditions. The program may include open-market purchases, block trades, and exchange transactions, with the flexibility to suspend or discontinue at any time.
Sensus Healthcare (NASDAQ: SRTS) reported strong Q4 and full-year 2024 results, marking its fifth consecutive quarter of profitability. Q4 revenues reached $13.1 million with net income of $1.5 million ($0.09 per diluted share). The company achieved record shipments of 39 SRT systems in Q4 and 115 systems for the full year, representing increases of 18% and 74% respectively.
Full-year 2024 revenues grew 71% to $41.8 million, with net income of $6.6 million ($0.41 per diluted share). The company maintains a strong financial position with $22.1 million in cash and no debt. Management expects Q1 2025 sales to be lower than Q1 2024, though anticipating full-year growth. The company continues to expand its Fair Deal Agreement program and plans to re-submit its TDI 510(k) application in H1 2025.
Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive and minimally-invasive treatments for skin conditions, has announced its upcoming participation in The Microcap Conference 2025. The event will take place from January 28-30, 2025, in Atlantic City, N.J.
The company's management team will deliver a corporate presentation on Thursday, January 30, 2025, at 2:00 PM Eastern Time in Studio 2 of the Borgata Hotel Casino & Spa. During the conference, management will engage in one-on-one meetings with institutional and individual investors to discuss recent developments, growth strategy, and investment opportunities.
Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive and minimally-invasive treatments for skin conditions, has scheduled its 2024 fourth quarter and full year financial results announcement for Wednesday, February 5, 2025. The company will host a conference call at 4:30 p.m. Eastern time to discuss results and provide a business update.
Participants can pre-register for the call through a provided link for a unique dial-in number, or join by dialing 844-481-2811 (U.S./Canada) or 412-317-0676 (International). The call will be webcast live and available for replay until March 5th, with replay numbers provided for U.S., Canada, and International callers.
Sensus Healthcare (NASDAQ: SRTS) has partnered with Pompano Veterinary Oncology to pioneer mobile superficial radiotherapy (SRT) treatment for companion animals in South Florida. The veterinary practice has purchased an SRT-100™ system to provide treatments via a mobile van, both for home visits and veterinary clinics.
This marks the fourth SRT system being used for animal treatment, with two systems at Colorado State University School of Veterinary Medicine and one at Beit Veri College in Tel Aviv. The mobile service will complement Pompano Veterinary Oncology's existing treatments, including chemotherapy, immunotherapy, surgery, and tumor-specific electroporation therapy.
Sensus Healthcare (NASDAQ: SRTS) reported strong Q3 2024 financial results with revenues reaching $8.8 million, a 127% increase from $3.9 million in Q3 2023. The company achieved net income of $1.2 million ($0.07 per diluted share) compared to a net loss of $1.5 million in the prior year. Key highlights include shipping 27 systems, entering seven new Fair Deal Agreements for SRT-100 Vision units, and maintaining a strong balance sheet with $22.6 million in cash and no debt. The company expects to have over 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by year-end.
Sensus Healthcare (SRTS) reported strong Q3 2024 financial results with revenues more than doubling to $8.8 million compared to $3.9 million in Q3 2023. The company achieved net income of $1.2 million ($0.07 per diluted share) versus a net loss of $1.5 million in the prior year. They shipped 27 systems during the quarter and signed a significant Fair Deal Agreement with Platinum Dermatology, a network of 130 dermatology clinics. The company maintained a strong financial position with $22.6 million in cash and no debt. Gross profit margin improved to 59.3% from 51.0% year-over-year.